Format

Send to

Choose Destination
J Pediatric Infect Dis Soc. 2016 Sep;5(3):303-11. doi: 10.1093/jpids/piv027. Epub 2015 May 20.

Incidence, Morbidity, and Costs of Human Metapneumovirus Infection in Hospitalized Children.

Author information

1
Department of Pediatrics, University of Utah Health Sciences Center, Salt Lake City.
2
Department of Pediatrics, University of Utah Health Sciences Center, Salt Lake City Intermountain Healthcare, Salt Lake City, Utah.
3
Intermountain Healthcare, Salt Lake City, Utah.

Abstract

BACKGROUND:

Human metapneumovirus (HMPV) causes acute respiratory tract infections in infants and children. We sought to measure the clinical and economic burden of HMPV infection in hospitalized children.

METHODS:

We conducted a retrospective cohort study from 2007 to 2013 at Primary Children's Hospital in Salt Lake City, Utah. Children <18 years of age with laboratory-confirmed HMPV infection were included. Demographic, clinical, and financial data were abstracted from the electronic medical record.

RESULTS:

During the study period, 815 children were hospitalized with laboratory-confirmed HMPV infection: 16% <6 months, 50% 6-23 months, 23% 2-4 years, and 11% 5-17 years of age. A complex chronic condition was identified in 453 (56%) children hospitalized with HMPV infection; this proportion increased with increasing age (P < .001). There was marked variation in annual HMPV hospitalization rates, ranging from 9 of 100 000 person-years in 2012-2013 to 79 of 100 000 in 2009-2010. Hospitalization rates were highest among children <2 years (200 of 100 000 person-years) and lowest among children 5-17 years of age (5 of 100 000). Of hospitalized children, 18% were treated in the intensive care unit and 6% required mechanical ventilation. The median length of stay was 2.8 days (interquartile range [IQR], 1.8-4.6) and did not vary by age. The median total hospital cost per patient was $5513 (IQR, $3850-$9946) with significantly higher costs for patients with chronic medical conditions (P < .001).

CONCLUSIONS:

Human metapneumovirus infection results in a large number of hospitalizations with substantial morbidity, resource utilization, and costs. The development of a safe and effective vaccine could reduce the clinical and economic burden of HMPV.

KEYWORDS:

HMPV; complications; disease severity; hospital cost; human metapneumovirus

PMID:
26407261
PMCID:
PMC5125451
DOI:
10.1093/jpids/piv027
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center